Sex differences in myocardial infarct size are abolished by sarcolemmal KATP channel blockade in rat. Am J Physiol Heart Circ Physiol 290: H2644 -H2647, 2006. First published February 10, 2006 doi:10.1152/ajpheart.01291.2005.-This study was conducted to examine the relationship between myocardial ATP-sensitive potassium (KATP) channels and sex differences in myocardial infarct size after in vitro ischemia-reperfusion (I/R). Hearts from adult male and female Sprague-Dawley rats were excised and exposed to an I/R protocol (1 h of ischemia, followed by 2 h of reperfusion) on a modified Langendorff apparatus. Hearts from female rats showed significantly smaller infarct sizes than hearts from males (23 Ϯ 4 vs. 40 Ϯ 5% of the zone at risk, respectively; P Ͻ 0.05). Administration of HMR-1098, a sarcolemmal K ATP channel blocker, abolished the sex difference in infarct size (42 Ϯ 4 vs. 45 Ϯ 5% of the zone at risk in hearts from female and male rats, respectively; P ϭ not significant). Further experiments showed that blocking the KATP channels in ischemia, and not reperfusion, was sufficient to increase infarct size in female rats. These data demonstrate that sarcolemmal KATP channels are centrally involved in mechanisms that underlie sex differences in the susceptibility of the intact heart to I/R injury. heart; ischemia; reperfusion ISCHEMIC HEART DISEASE is the leading cause of death in both males and females in the industrialized world, with myocardial infarction being the most common manifestation of ischemic heart disease (18). Among humans, premenopausal women have a lower risk of cardiovascular disease than age-matched men, and there is growing evidence that there is a sex-specific difference in the susceptibility of the myocardium to infarction after ischemia in dogs (15), rats (1, 4), mice (10, 11), as well as in humans (19).
ISCHEMIC HEART DISEASE is the leading cause of death in both males and females in the industrialized world, with myocardial infarction being the most common manifestation of ischemic heart disease (18) . Among humans, premenopausal women have a lower risk of cardiovascular disease than age-matched men, and there is growing evidence that there is a sex-specific difference in the susceptibility of the myocardium to infarction after ischemia in dogs (15) , rats (1, 4) , mice (10, 11) , as well as in humans (19) .
The cellular basis for sex differences in the susceptibility of the heart to ischemia-reperfusion (I/R) injury has not been elucidated. However, there has been speculation that that sarcolemmal ATP-sensitive potassium (sarcK ATP ) channels are involved. This speculation derives from observations that, relative to males, the protein expression of sarcK ATP channel subunits [inwardly rectifying K ϩ (Kir)6.2 and sulfonylurea receptor (SUR)2a] is greater in hearts from females (4, 26) . Additionally, treatment of heart-derived H9c2 cells with 17␤-estradiol elicits a marked increase in the expression of both Kir6.2 and SUR2a subunits and an increase in the resistance of those cells to hypoxia-induced Ca 2ϩ overload that, in turn, could be abolished by sarcK ATP channel blockade with HMR-1098 (25) . Whereas these observations clearly implicate a role for sarcK ATP channels in the sex-dependent differences in the susceptibility of the heart to I/R injury, pharmacological blockade of sarcK ATP channels in the intact heart has not been performed to confirm their role in sex-dependent cardioprotection. Thus the major objective of this study was to determine whether blocking sarcK ATP channels would abolish the sex difference in myocardial infarct size after I/R.
METHODS
Experimental animals. Adult male and female Sprague-Dawley rats (Harlan) were used in the study (n ϭ 43 animals in total). All animals were provided food (standard rat chow) and water ad libitum. All experiments were conducted with prior approval from the Institutional Animal Care and Use Committee at the University of Colorado at Boulder and in accordance with guidelines established by the American Physiological Society.
Infarct size measurements. The I/R protocol and the measurement of myocardial infarct size employed were identical to the protocol previously described in detail by our laboratory (2, 3, 4) . Briefly, hearts were isolated and perfused on a modified Langendoff apparatus and, after 15 min of "baseline" perfusion, were subjected to 1 h of regional ischemia, followed by 2 h of reperfusion. Detailed descriptions and schematics of the I/R protocol used in each of our studies and the times during which HMR-1098 (30 M) was administered to the hearts can be found in Figs. 1 and 2 and in their respective legends.
Statistical analysis. Infarct sizes between groups were compared using a 2 ϫ 2 ANOVA. Significant main effects of both drug (control vs. HMR-1098) and sex difference were followed by a two-tailed Student's t-test between groups for comparison. The temporal effect of HMR-1098 administration on infarct size was analyzed by using a one-way ANOVA, followed by Bonferroni-corrected post hoc tests. A P Ͻ 0.05 value was chosen to indicate statistical significance.
RESULTS
Infarct size. The mean zone at risk (ZAR) for the experimental groups ranged from 39 -44% of the left ventricle, with no significant differences between experimental groups. Hearts from female rats exhibited significantly less I/R damage ( Fig.  1 ) than those of their male counterparts (23 Ϯ 4 vs. 40 Ϯ 5% of the ZAR, P ϭ 0.038). The addition of HMR-1098 during the I/R protocol abolished the sex difference in myocardial infarct size [42 Ϯ 4 vs. 45 Ϯ 5% of the ZAR in hearts from female and male rats, respectively, P ϭ not significant (NS); Fig. 1 ]. Whereas the presence of HMR-1098 had no effect on infarct size in male hearts exposed to I/R, infarct size increased by 82% in female hearts perfused with HMR-1098 during the 3-h I/R protocol (P ϭ 0.013).
Data pertaining to the effect of HMR-1098 perfusion on infarct size during different time points in the protocol are presented in Fig. 2 . Acute administration of HMR-1098 for 5 min before the ischemic period increased infarct size from 23 Ϯ 4 to 52 Ϯ 3% of the ZAR (P ϭ 0.001). To the contrary, infarct size, after the addition of HMR-1098 during the reperfusion period only, was not different from that of control hearts (23 Ϯ 3% of the ZAR; P ϭ NS). Infarct size after 3 h of HMR-1098 administration was not statistically different from infarct size when HMR-1098 was administered immediately before ischemia (42 Ϯ 4 vs. 52 Ϯ 3% of the ZAR, respectively; P ϭ NS).
DISCUSSION
The majority, but not all (16, 24) , of the studies performed on a wide variety of experimental animal models provide strong evidence that myocardium from females, relative to males, is intrinsically more resistant to I/R-induced tissue injury and infarction (1, 4, 7, 10, 15, 19) . The data in this study corroborate these findings (Fig. 1) . The reasons for the lack of complete consensus on this issue are not known, but the basis for the disparate findings may be related to the interpretive complexities associated with the use of different animals models and analytical methodologies. Additionally, it is apparent that the cellular basis for sex differences in the susceptibility of the heart to infarction is probably quite complex and to date has eluded clear description. To begin to address this issue, this study was conducted to determine the potential contribution of sarcK ATP channels in sex-specific resistance to myocardial infarction.
In our earlier work (4), we found that the cardioprotection associated with female sex was accompanied by a greater protein expression of the sarcK ATP channel subunits. The present study provides the first demonstration in the intact heart that blockade of sarcK ATP channels during in vitro I/R abrogates the sex difference in myocardial infarct size and implicates sarcK ATP channels as being required mediators of enhanced protection in female rats. Previous studies from Jovanovic's laboratory (26) on isolated cell systems have shown that cardiocytes from female hearts expressed a greater pinacidil-induced outward current and were more resistant to cellular calcium overload than cells from male hearts. A subsequent study by this group (25) indicated that 17-␤ estradiol increased sarcK ATP channel expression (and is protective against hypoxia reoxygenation-induced cell injury) in a heart-derived H9c2 cell line and that K ATP channel antagonist abolished the protection afforded by 17-␤ estradiol. The data presented herein provide a crucial extension of these studies in that they clearly demonstrate that the sarcK ATP channel-dependent cardioprotection in females is present in the whole heart and that the temporal Fig. 1 . Blockade of sarcolemmal ATP-sensitive potassium (sarcKATP) channels abolishes sex difference in infarct size in hearts from male and female rats. Hearts from male and female animals were used in 2 experimental groups: those that received buffer with no drug (control) throughout the protocol (n ϭ 7 males and 6 females; all animal numbers represent the number of hearts included in data analysis) and those that received 30 M HMR-1098 (HMR), a specific sarcKATP channel agonist (see Ref. 13) . In hearts treated with HMR, the drug was administered 3 min before coronary artery occlusion and then continuously throughout the 3 h of I/R protocol for hearts from male (n ϭ 6) and female (n ϭ 7) rats (see protocol schematic, bottom). Concentration of HMR used in this study has been previously used by our laboratory and others (see Refs. 2, 6, 9, 15) and does not elicit significant infarction when administered in the absence of ischemia (see Ref. 2) . ZAR, zone at risk. *P Ͻ 0.05, male control vs. female control; **P Ͻ 0.02, female control vs. female HMR. Fig. 2 . Sex-dependent effect of sarcKATP channel blockade on infarct size in intact hearts is confined to the ischemia phase of the I/R protocol. Because only hearts from female rats were influenced by HMR, we used additional hearts from female rats that were perfused with HMR (30 M) only during ischemia (I only; n ϭ 4) or only during reperfusion (R only; n ϭ 5) to determine when in the I/R protocol sarcKATP channel blockade increased infarct size in hearts from female rats (see protocol schematic, bottom). Infarct size was significantly expanded by I-only HMR perfusion (*P Ͻ 0.05 vs. control) but was not affected by R-only HMR perfusion. involvement of sarcK ATP channels in the cardioprotective process is most important during the ischemic, rather than the reperfusion, phase of I/R stress.
Blocking the sarcK ATP channel population in male rats had no effect on myocardial infarct size (Fig. 1) . These data are consistent with a number of studies indicating that sarcK ATP channel blockade during an I/R protocol does not alter infarct size in hearts from male rats (13, 21) and support our evidence that a sex-specific difference in K ATP channel-induced protection from myocardial infarction is present. It is also noteworthy that in nonpreconditioned hearts from both male (21, 27) and female (2) rats, it has been demonstrated that the putative mitochondrial K ATP channel antagonist 5-hydroxydecanoate (5-HD) has no effect on infarct size, suggesting that mitochondrial K ATP channels do not play a central role in the sexdependent differences in the susceptibility of the heart to myocardial infarction. This also indicates that the intrinsic, sex-dependent resistance of the heart to I/R injury is not analogous to a broad array of acquired cardioprotection models, almost all of which have been shown to be 5-HD sensitive (5, 8, 9, 14, (21) (22) (23) . One notable exception is cardioprotection acquired by long-term exercise, which has recently been shown to be HMR-1098 sensitive and 5-HD insensitive (2); interestingly, this study was conducted on female rats.
Although the exact mechanisms whereby K ATP channels may provide protection in female, but not male, hearts require further experimentation, our results are intriguing in light of a very recent study by Bae and Zhang (1). These investigators found that the smaller infarct size in female hearts was related to an increased activity of protein kinases B (also called Akt) and C. Analogous to our findings (Fig. 1) , inhibition of these kinases before ischemia resulted in expanded infarct size in female, but not male, hearts. Given the fact that protein kinases have been widely shown to influence the activity of myocardial K ATP channels (for review articles, see Refs. 6, 17, 20, and 28), an interesting sex-specific cascade of events incorporating receptor activation, second messenger signaling, K ATP channel phosphorylation, and, ultimately, cardioprotection may be slowly emerging. Obviously, future experiments will be needed to elucidate the specific sex differences in cellular strategies of cardioprotection.
In summary, we have shown that inhibition of sarcK ATP channels during ischemia abolishes the sex difference in infarct size, providing evidence that hearts from males and females may respond to ischemia via very different mechanisms. Given the prevalence of studies examining both paradigms of preconditioning and intrinsic protection from infarction, our hope is that further attention will be given to the sex of animals studied to further explore sex differences in the susceptibility of the myocardium to I/R injury.
